Combined Serum DKK3 and Circulating CD133 Cells as Prognostic Biomarkers for Ovarian Cancer Patients

INTRODUCTION: Ovarian cancer (OV) can seriously endanger women’s physical and mental health. Serum DKK3 has been used for the diagnosis and prognosis of patients with ovarian cancer. However, the specificity of antibodies may lead to errors in the detection of plasma protein. METHODS: Circulating CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Xiao-Cui, He, Fang, Lan, Chong, Niu, Ju-Min, Xia, Pu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814242/
https://www.ncbi.nlm.nih.gov/pubmed/33488097
http://dx.doi.org/10.2147/OTT.S288191
_version_ 1783638022759120896
author Nie, Xiao-Cui
He, Fang
Lan, Chong
Niu, Ju-Min
Xia, Pu
author_facet Nie, Xiao-Cui
He, Fang
Lan, Chong
Niu, Ju-Min
Xia, Pu
author_sort Nie, Xiao-Cui
collection PubMed
description INTRODUCTION: Ovarian cancer (OV) can seriously endanger women’s physical and mental health. Serum DKK3 has been used for the diagnosis and prognosis of patients with ovarian cancer. However, the specificity of antibodies may lead to errors in the detection of plasma protein. METHODS: Circulating CD133(+) cells from blood samples were separated by magnetic microbeads. Serum DKK3 levels were determined by ELISA. The roles of DKK3 in OV cells were analyzed in vitro. RESULTS: In this study, we found that the CD133(+) subpopulation in circulating tumor cells can indicate the overall survival rate of OV patients. Serum DKK3 levels were negatively correlated with the number of circulating CD133(+) cells in OV patients. In addition, we confirmed the inhibitory effect of recombinant human DKK3 (rhDKK3) on OV cells via reversal of the epithelial–mesenchymal transition (EMT) process. CONCLUSION: Both serum DKK3 levels and circulating CD133(+) tumor cells can be used as prognostic markers for patients with ovarian cancer.
format Online
Article
Text
id pubmed-7814242
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78142422021-01-21 Combined Serum DKK3 and Circulating CD133 Cells as Prognostic Biomarkers for Ovarian Cancer Patients Nie, Xiao-Cui He, Fang Lan, Chong Niu, Ju-Min Xia, Pu Onco Targets Ther Original Research INTRODUCTION: Ovarian cancer (OV) can seriously endanger women’s physical and mental health. Serum DKK3 has been used for the diagnosis and prognosis of patients with ovarian cancer. However, the specificity of antibodies may lead to errors in the detection of plasma protein. METHODS: Circulating CD133(+) cells from blood samples were separated by magnetic microbeads. Serum DKK3 levels were determined by ELISA. The roles of DKK3 in OV cells were analyzed in vitro. RESULTS: In this study, we found that the CD133(+) subpopulation in circulating tumor cells can indicate the overall survival rate of OV patients. Serum DKK3 levels were negatively correlated with the number of circulating CD133(+) cells in OV patients. In addition, we confirmed the inhibitory effect of recombinant human DKK3 (rhDKK3) on OV cells via reversal of the epithelial–mesenchymal transition (EMT) process. CONCLUSION: Both serum DKK3 levels and circulating CD133(+) tumor cells can be used as prognostic markers for patients with ovarian cancer. Dove 2021-01-14 /pmc/articles/PMC7814242/ /pubmed/33488097 http://dx.doi.org/10.2147/OTT.S288191 Text en © 2021 Nie et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Nie, Xiao-Cui
He, Fang
Lan, Chong
Niu, Ju-Min
Xia, Pu
Combined Serum DKK3 and Circulating CD133 Cells as Prognostic Biomarkers for Ovarian Cancer Patients
title Combined Serum DKK3 and Circulating CD133 Cells as Prognostic Biomarkers for Ovarian Cancer Patients
title_full Combined Serum DKK3 and Circulating CD133 Cells as Prognostic Biomarkers for Ovarian Cancer Patients
title_fullStr Combined Serum DKK3 and Circulating CD133 Cells as Prognostic Biomarkers for Ovarian Cancer Patients
title_full_unstemmed Combined Serum DKK3 and Circulating CD133 Cells as Prognostic Biomarkers for Ovarian Cancer Patients
title_short Combined Serum DKK3 and Circulating CD133 Cells as Prognostic Biomarkers for Ovarian Cancer Patients
title_sort combined serum dkk3 and circulating cd133 cells as prognostic biomarkers for ovarian cancer patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814242/
https://www.ncbi.nlm.nih.gov/pubmed/33488097
http://dx.doi.org/10.2147/OTT.S288191
work_keys_str_mv AT niexiaocui combinedserumdkk3andcirculatingcd133cellsasprognosticbiomarkersforovariancancerpatients
AT hefang combinedserumdkk3andcirculatingcd133cellsasprognosticbiomarkersforovariancancerpatients
AT lanchong combinedserumdkk3andcirculatingcd133cellsasprognosticbiomarkersforovariancancerpatients
AT niujumin combinedserumdkk3andcirculatingcd133cellsasprognosticbiomarkersforovariancancerpatients
AT xiapu combinedserumdkk3andcirculatingcd133cellsasprognosticbiomarkersforovariancancerpatients

Ejemplares similares